Key result
High DCM polygenic risk score is linked to ~82% higher odds of peripartum cardiomyopathy.
Why the study?
Does a high dilated cardiomyopathy polygenic risk score increase the risk of peripartum, alcohol-induced, and cancer therapy-related cardiomyopathies?
Cohort (n=1,271,313)
Yes
Does a high dilated cardiomyopathy polygenic risk score increase the risk of peripartum, alcohol-induced, and cancer therapy-related cardiomyopathies?
Answers are grounded in this paper and cite their sources.
A high polygenic risk score for dilated cardiomyopathy is significantly associated with an increased risk of developing secondary cardiomyopathies, including peripartum, alcohol-induced, and cancer therapy-related cardiomyopathies.
Importance Rare monogenic variants linked to nonischemic dilated cardiomyopathy (DCM) are enriched among individuals with secondary cardiomyopathies, such as peripartum (PPCM), alcohol-induced (ACM), and cancer therapy–related (CCM) cardiomyopathies. However, it remains unclear whether a polygenic predisposition to DCM also contributes to these conditions. Objective To assess the association of a DCM polygenic score with PPCM, ACM, and CCM, and to evaluate the contributions of monogenic and polygenic susceptibilities to these secondary cardiomyopathies. Design, Setting, and Participants This was a retrospective genetic association analysis of data from the Mass General Brigham (MGB) Biobank (n = 42 137, 2008-2025), with replication in the UK Biobank (n = 295 160, 2005-2010), FinnGen (n = 417 950, 2017-2025), and the Veterans Affairs Million Veteran Program (n = 516 066, 2011-2025). In MGB Biobank, medical records were reviewed to ascertain secondary cardiomyopathy cases and antecedent clinical risk factors. Exposures DCM polygenic risk score and DCM monogenic variants. Main Outcomes and Measures The primary outcomes were the association of the DCM polygenic risk score with PPCM, ACM, and CCM and the prevalence of monogenic variants and a high polygenic score among individuals with cardiomyopathy. Results The mean (SD) age in the MGB Biobank was 55.7 (17.0) years at enrollment, and 24 551 (58.3%) were female. Across the 4 study cohorts, 3414 individuals with secondary cardiomyopathy were identified, including 70 with PPCM, 2281 with ACM, and 1063 with CCM. The DCM polygenic score was associated with PPCM (odds ratio [OR], 1.82 per SD; 95% CI, 1.43-2.30), ACM (OR, 1.56; 95% CI,1.34-1.82), and CCM (OR, 1.64; 95% CI,1.24-2.15) (all with P < .001). Monogenic variants were enriched but present in 7 of 113 individuals with medical record–reviewed cardiomyopathy in MGB, while 66 had a high polygenic score, which conferred an approximately 3-fold increased odds of cardiomyopathy. Most individuals with cardiomyopathy lacked antecedent clinical risk factors. Conclusions and Relevance In this cohort study, individuals with PPCM, ACM, and CCM were enriched for monogenic DCM variants and a high DCM polygenic score, suggesting a shared genetic susceptibility influenced by distinct environmental precipitants. These findings support a shared genetic architecture between secondary cardiomyopathies and DCM, although additional work with larger numbers of individuals with cardiomyopathy is needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Maamari et al. (2025) conducted a cohort in Secondary cardiomyopathies (peripartum, alcohol-induced, cancer therapy-related) (n=1,271,313). DCM polygenic risk score vs. Lower polygenic risk score was evaluated on Association of the DCM polygenic risk score with peripartum cardiomyopathy (PPCM) (OR 1.82, 95% CI 1.43-2.30, p=<0.001). A higher DCM polygenic risk score was associated with increased odds of peripartum, alcohol-induced, and cancer therapy-related cardiomyopathies.
Synapse has enriched 10 related papers. Consider them for comparative context: